JP2005514459A - フェンセリン及びその類似体を生成するための方法 - Google Patents
フェンセリン及びその類似体を生成するための方法 Download PDFInfo
- Publication number
- JP2005514459A JP2005514459A JP2003560012A JP2003560012A JP2005514459A JP 2005514459 A JP2005514459 A JP 2005514459A JP 2003560012 A JP2003560012 A JP 2003560012A JP 2003560012 A JP2003560012 A JP 2003560012A JP 2005514459 A JP2005514459 A JP 2005514459A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- reaction medium
- etheroline
- phenserine
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- PBHFNBQPZCRWQP-QUCCMNQESA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-phenylcarbamate Chemical compound CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-QUCCMNQESA-N 0.000 title description 22
- 238000000034 method Methods 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- -1 phenserine compound Chemical class 0.000 claims abstract description 32
- 239000012948 isocyanate Substances 0.000 claims abstract description 23
- 150000002513 isocyanates Chemical class 0.000 claims abstract description 23
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960001697 physostigmine Drugs 0.000 claims abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000012429 reaction media Substances 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 239000003960 organic solvent Substances 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 11
- 239000012431 aqueous reaction media Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 150000007530 organic bases Chemical class 0.000 claims description 9
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical group [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 8
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical group COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical group O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 claims description 4
- 150000005215 alkyl ethers Chemical class 0.000 claims description 3
- 229960001860 salicylate Drugs 0.000 claims description 3
- 150000003873 salicylate salts Chemical group 0.000 claims 2
- 230000003750 conditioning effect Effects 0.000 claims 1
- 229910000000 metal hydroxide Inorganic materials 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 7
- 230000007062 hydrolysis Effects 0.000 abstract description 4
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract description 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 20
- 239000002585 base Substances 0.000 description 15
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical class C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- XKKPTCVQEJZDGT-PWUAAHBCSA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-phenylcarbamate;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 XKKPTCVQEJZDGT-PWUAAHBCSA-N 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000010537 deprotonation reaction Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- HKGWQUVGHPDEBZ-OLZOCXBDSA-N eseroline Chemical compound C1=C(O)C=C2[C@]3(C)CCN(C)[C@@H]3N(C)C2=C1 HKGWQUVGHPDEBZ-OLZOCXBDSA-N 0.000 description 2
- KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 0 CC12c3cc(OC(N*)=O)ccc3N(*)C1N(*)CC2 Chemical compound CC12c3cc(OC(N*)=O)ccc3N(*)C1N(*)CC2 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical group [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000005496 phosphonium group Chemical group 0.000 description 1
- 229960002516 physostigmine salicylate Drugs 0.000 description 1
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical group 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
にて示されるフェンセリン及びフェンセリン類似体が、以下の式Iに示すフィソスチグミン化合物及びその塩から、以下の式IIに示すエセロリン化合物を介して調製され、その際、該式IIの化合物と以下の式Vのイソシアン酸塩との反応により調製され;
本発明の方法に従って、式Iのフィソスチグミン化合物又はその塩は、水性反応媒体中にて、式Iのフィソスチグミン化合物のアルカリ金属水酸化物での加水分解により式IIのエセロリン化合物を形成するように反応にかけられる。次いで、式IIのエセロリン化合物は水性反応媒体から純粋な形にて単離される。
アルゴン雰囲気下にて、50重量%の水酸化ナトリウム溶液(67.7g、0.8462モル)を、45℃にて脱気した脱イオン水(DI water)(300mL)中のサリチル酸フィソスチグミン(100g、0.2418モル)スラリー中に滴下した。添加時、温度は45乃至55℃に維持された。45℃にて約3時間経過した後、黄色の溶液を25乃至30℃に冷却し、tert.−ブチルメチルエーテル(300mL)を加えた。水相のpHはメタ重亜硫酸ナトリウム(sodium meta bisulfite)水溶液(54g、Na2S2O5、250mLの水)で9.1に調整した。混合物は30分間撹拌し、相を静置させて、分離させた。水相はtert.−ブチルメチルエーテル(各300mL)にて各々が30分間の時間にて2回抽出した。有機相を混合し、20重量%の塩化ナトリウム溶液(各200mL)を用いて三回洗浄し、硫酸マグネシウム(150g)にて一晩乾燥させた。スラリーはセライトを用いてろ過し、ろ取したケーキはtert.−ブチルメチルエーテルにて洗浄した。ろ液を25乃至29インチ(63.5乃至73.7cm)の真空にて300mLに濃縮し、残渣はジエトキシメタン(各300mL)にて2回共蒸留した。残渣をジエトキシメタン(300mL)にて希釈し、50℃に加熱した。得られた淡色のスラリーを5℃に冷却し、45分間撹拌し、約300mLに濃縮した。冷ヘプタン(300mL)を滴下し、スラリーを20分間撹拌し、冷ヘプタン(125mL)を添加することにより容量を増加させた。約2時間撹拌した後、該スラリーをブフナー漏斗にてろ過した。回収された固形物は冷ヘプタン(200mL)で洗浄し、真空中にて一晩乾燥させた。エセロリン塩基(36.5g)が白色固体として得られ、収率は67.4%であり、純度は98.3%であった。
エセロリン塩基(50g、0.229モル)はアルゴン雰囲気下にて無水のジメトキシエタン400mLに溶解した。触媒量の2.5Mのn−ブチルリチウムのヘキサン溶液(6.4mL、16ミリモル)を1分以内に加え、該溶液を10分間撹拌した。フェニルイソシアネート(27.269g、0.2286ミリモル)を、32分間にわたり20乃至23℃の温度を維持しながら加えた。反応溶液を室温にて2時間20分撹拌し、付加ろ過器(addition funnel)に移した。反応溶液は脱イオン水(630mL)及びジメトキシエタン(42mL)の混合物中に、49分間にわたり強く撹拌しながら加えた。得られたスラリーを30分間撹拌し、ブフナー漏斗(ワットマン#3ろ紙)にてろ過した。固体残渣を脱イオン水(各100mL)で4回洗浄し、ヘプタン(100mL)にて1回洗浄し、45℃、かつ29インチ(73.7cm)以上の真空(>29 inches of vacuum)にて、9時間乾燥した。フェンセリン塩基(74.4g)は赤みを帯びた固体として得られ、収率は96.2%であり、純度は95.1%であった。
アルゴン雰囲気下にて、無水エタノール(131mL)及び脱イオン水(3.3mL)の混合物中の酒石酸溶液(17.12g、0.114モル)を、無水エタノール(126mL)及び脱イオン水(3.1mL)の混合物中のフェンセリン塩基(35g、0.1037モル)のスラリー中に32分間にわたって加えた。酒石酸溶液の約60乃至75%が加えられた後に、反応溶液からフェンセリン酒石酸塩(72mg)が供給(seed)された。反応混合物を室温にて19時間15分撹拌し、イソプロパノール(490mL)及び水(12mL)の混合物を30分間にわたり加えた。スラリーを3.5時間撹拌し、ブフナー漏斗(ワットマン#3ろ紙)にてろ過した。白色の残渣をイソプロパノール(100mL)にて2回洗浄し、45℃、かつ29インチ(73.7cm)にて19時間乾燥し、フェンセリン酒石酸塩(38.62g)を、収率76%、純度99.4%の白色固体として得た。
Claims (24)
- 前記反応媒体は不活性かつ水と混和しない有機溶媒を含む請求項1に記載の方法。
- 前記Rはメチルである請求項2に記載の方法。
- 前記式Iの化合物は塩である請求項3に記載の方法。
- 前記塩はサリチル酸塩である請求項4に記載の方法。
- 前記アルカリ金属水酸化物は水酸化ナトリウムである請求項5に記載の方法。
- 前記水と混和しない溶媒は低級アルキルエーテルである請求項2に記載の方法。
- 前記調整はアルカリ金属重亜硫酸塩の添加によって実施される請求項8に記載の方法。
- 前記水性媒体は不活性かつ水と混和しない有機溶媒を含む請求項9に記載の方法。
- 前記有機溶媒は低級アルキルエーテルである請求項10に記載の方法。
- 前記フィソスチグミン化合物は酸付加塩である請求項11に記載の方法。
- 前記塩はサリチル酸塩である請求項12に記載の方法。
- 以下の式に示すフェンセリン化合物又はその塩を製造する方法において、
前記方法は、
a)以下の式に示す精製されたエセロリン化合物;
を不活性かつ非プロトン性の水と混和性の有機溶媒を含む無水反応媒体中にて有機塩基で処理する工程と、
b)前記反応媒体中において、前記処理されたエセロリン化合物を以下の式に示すイソシアン酸塩と反応させる工程と、
前記反応工程は前記フェンセリン化合物を生成するために前記イソシアン酸塩を前記反応媒体と混合することにより実施されることと、
からなる方法。 - 前記水と混和性の溶媒はジメトキシエタンである請求項14に記載の方法。
- 前記有機塩基はブチルリチウムである請求項15に記載の方法。
- 前記Rはメチルであり、かつ前記イソシアン酸塩はフェニルイソシアネートである請求項15に記載の方法。
- フェンセリン化合物を生成した後に前記反応媒体に水を加えて該反応媒体中に形成されたフェンセリン化合物を沈殿させる工程を更に含む請求項14に記載の方法。
- 以下の式に示すフェンセリン化合物を製造する方法において、
前記方法は、
a)以下の式に示すフィソスチグミン化合物又はその塩;
を12乃至14のpHにて水と混和性の溶媒の非存在下で水性反応媒体中にてアルコキシド金属水酸化物で加水分解して、前記水性反応媒体中に以下の式にて示すエセロリン化合物を形成する工程と;
c)前記精製されたエセロリン化合物を不活性かつ非プロトン性の水と混和性の有機溶媒を含む無水反応媒体中にて有機塩基で処理する工程と、
d)前記処理されたエセロリン化合物を以下の式にて示すイソシアン酸塩と反応させる工程と、
該反応工程は前記フェンセリン化合物を生成するために前記イソシアン酸塩を前記無水反応媒体と混合することにより実施されることと、
からなる方法。 - 前記有機塩基はn−ブチルリチウムである請求項19に記載の方法。
- 前記水と混和性の溶媒はジメトキシエタンである請求項19に記載の方法。
- 前記Rはメチルであり、かつ前記イソシアン酸塩はフェニルイソシアネートである請求項21に記載の方法。
- フェンセリン化合物を生成した後に前記無水反応媒体に水を加え、それにより該フェンセリン化合物を沈殿させる工程を更に含む請求項19に記載の方法。
- 前記調整はアルカリ金属重亜硫酸塩を加えることにより実施される請求項19に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/042,586 US6495700B1 (en) | 2002-01-09 | 2002-01-09 | Process for producing phenserine and its analog |
PCT/US2002/039537 WO2003059909A1 (en) | 2002-01-09 | 2002-12-11 | A process for producing phenserine and its analog |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005514459A true JP2005514459A (ja) | 2005-05-19 |
JP2005514459A5 JP2005514459A5 (ja) | 2005-12-22 |
Family
ID=21922704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003560012A Pending JP2005514459A (ja) | 2002-01-09 | 2002-12-11 | フェンセリン及びその類似体を生成するための方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US6495700B1 (ja) |
EP (1) | EP1463729B1 (ja) |
JP (1) | JP2005514459A (ja) |
KR (2) | KR100712003B1 (ja) |
CN (1) | CN1301995C (ja) |
AT (1) | ATE466015T1 (ja) |
AU (1) | AU2002353102B2 (ja) |
BR (1) | BRPI0215492A2 (ja) |
CA (1) | CA2470560C (ja) |
DE (1) | DE60236207D1 (ja) |
HR (1) | HRP20040606A2 (ja) |
HU (1) | HUP0500747A3 (ja) |
IL (1) | IL162827A0 (ja) |
PL (1) | PL374240A1 (ja) |
WO (1) | WO2003059909A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4676961B2 (ja) | 2003-10-21 | 2011-04-27 | コルシド・ファーマシューティカルズ・インコーポレイテッド | コリンエステラーゼを阻害し、薬理活性物質を放出するカルバモイルエステル類 |
US20070167509A1 (en) * | 2005-06-14 | 2007-07-19 | Joseph Araujo | Use of phenserine and analogs to treat behavioral problems and improve trainability |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
AU2006282896A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
CA2662491A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
EP2533645B1 (en) | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
US20120225922A1 (en) | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
US20130096316A1 (en) * | 2011-10-14 | 2013-04-18 | Qr Pharma, Inc. | Novel Method for Preparation of Bisnorcymerine and Salts Thereof |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
US11160785B2 (en) | 2013-03-15 | 2021-11-02 | Agenebio Inc. | Methods and compositions for improving cognitive function |
HK1251980B (en) | 2015-05-22 | 2020-07-10 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
AU2016309815B2 (en) | 2015-08-14 | 2022-04-07 | Annovis Bio, Inc. | Methods of treatment or prevention of acute brain or nerve injuries |
EP3654957A4 (en) | 2017-05-24 | 2021-06-23 | Annovis Bio, Inc. | Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1109003B (it) * | 1977-09-20 | 1985-12-16 | Univ Firenze | Derivati dell 1 2 3 8 3 a 8 a esai dropirrolo 23 b indolo |
US5306825A (en) | 1984-03-01 | 1994-04-26 | Consiglio Nazionale Delle Ricerche | Physostigmine derivatives with acetylcholinesterase inhibition properties, and the relative production process |
IT1199076B (it) * | 1984-03-01 | 1988-12-30 | Consiglio Nazionale Ricerche | Derivati della fisostigmina con proprieta'di inibizione della aceticolinesterasi e relativo procedimento di produzione |
US4791107A (en) | 1986-07-16 | 1988-12-13 | Hoechst-Roussel Pharmaceuticals, Inc. | Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use |
IT1225462B (it) * | 1987-04-03 | 1990-11-14 | Mediolanum Farmaceutici Srl | Sali organici di derivati della fisostigmina |
US5187165A (en) | 1987-05-15 | 1993-02-16 | Hoechst-Roussel Pharmaceuticals Inc. | Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles |
US4900748A (en) | 1988-03-04 | 1990-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | Carbamates related to (-)-physostigmine as cholinergic agents |
US5260452A (en) | 1989-11-03 | 1993-11-09 | Hoechst-Roussel Pharmaceuticals Inc. | 4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof |
US5177101A (en) | 1989-11-30 | 1993-01-05 | Hoechst-Roussel Pharmaceuticals Incorporated | Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine |
US5077289A (en) | 1989-11-30 | 1991-12-31 | Hoechst Roussel Pharmaceuticals Inc. | Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine |
US5705657A (en) | 1991-02-14 | 1998-01-06 | Labochim Laboratorio Chimico Internazionale S.P.A. | Isocyanate process for the preparation of 1,3A,8-trimethyl-1,2,3,3A, 8, 8A-hexahydro-pyrrole 2,3-B! indol-5 (3AS, 8AR) -hepthylcarbamate |
EP0499959A1 (en) | 1991-02-18 | 1992-08-26 | Bromine Compounds Ltd. | Process for the manufacture of substituted maleimides |
DK0606366T3 (da) | 1991-09-26 | 2003-10-06 | Us Gov Health & Human Serv | Substituerede phenseriner og phenylcarbamater af (-)-eserolin, (-)-N1-noreserolin og (-)-N1-benzylnoreserolin som specifikke inhibitorer af acetylcholinesterase |
US5206260A (en) | 1991-11-07 | 1993-04-27 | Merck & Co., Inc. | Hexahydropyrrolo[2,3-b]indole derivatives |
US5302721A (en) | 1992-07-21 | 1994-04-12 | Hoechst-Roussel Pharmaceuticals Incorporated | Method of preparation of physostigmine carbamate derivatives from eseretholes |
FI933264A7 (fi) * | 1992-07-21 | 1994-01-22 | Hoechst Roussel Pharma | Foerfarande foer framstaellning av fysostigminkarbamatderivat fraon fysostigmin |
US5409948A (en) | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
US5665880A (en) | 1996-10-31 | 1997-09-09 | Hoechst Marion Roussel, Inc. | Method of preparation of physostigmine carbamate derivatives from eseretholes |
US5677457A (en) | 1996-12-19 | 1997-10-14 | Hoechst Marion Roussel, Inc. | Method of preparation of physostigmine carbamate derivatives from eseroline ethers |
-
2002
- 2002-01-09 US US10/042,586 patent/US6495700B1/en not_active Expired - Lifetime
- 2002-12-11 AU AU2002353102A patent/AU2002353102B2/en not_active Ceased
- 2002-12-11 IL IL16282702A patent/IL162827A0/xx unknown
- 2002-12-11 CN CNB028269985A patent/CN1301995C/zh not_active Expired - Fee Related
- 2002-12-11 KR KR1020047010683A patent/KR100712003B1/ko not_active Expired - Fee Related
- 2002-12-11 CA CA002470560A patent/CA2470560C/en not_active Expired - Fee Related
- 2002-12-11 BR BRPI0215492A patent/BRPI0215492A2/pt not_active IP Right Cessation
- 2002-12-11 KR KR1020067017072A patent/KR20060097772A/ko not_active Ceased
- 2002-12-11 JP JP2003560012A patent/JP2005514459A/ja active Pending
- 2002-12-11 AT AT02790077T patent/ATE466015T1/de active
- 2002-12-11 EP EP02790077A patent/EP1463729B1/en not_active Expired - Lifetime
- 2002-12-11 DE DE60236207T patent/DE60236207D1/de not_active Expired - Lifetime
- 2002-12-11 HR HRP20040606 patent/HRP20040606A2/hr not_active Application Discontinuation
- 2002-12-11 WO PCT/US2002/039537 patent/WO2003059909A1/en active IP Right Grant
- 2002-12-11 PL PL02374240A patent/PL374240A1/xx unknown
- 2002-12-11 HU HU0500747A patent/HUP0500747A3/hu unknown
Also Published As
Publication number | Publication date |
---|---|
AU2002353102A1 (en) | 2003-07-30 |
KR20040072711A (ko) | 2004-08-18 |
IL162827A0 (en) | 2005-11-20 |
AU2002353102B2 (en) | 2007-05-24 |
PL374240A1 (en) | 2005-10-03 |
CN1612880A (zh) | 2005-05-04 |
CA2470560C (en) | 2007-05-15 |
HUP0500747A2 (hu) | 2005-11-28 |
HRP20040606A2 (en) | 2004-12-31 |
EP1463729B1 (en) | 2010-04-28 |
BRPI0215492A2 (pt) | 2016-07-05 |
EP1463729A1 (en) | 2004-10-06 |
DE60236207D1 (de) | 2010-06-10 |
ATE466015T1 (de) | 2010-05-15 |
CA2470560A1 (en) | 2003-07-24 |
CN1301995C (zh) | 2007-02-28 |
WO2003059909A1 (en) | 2003-07-24 |
EP1463729A4 (en) | 2005-06-29 |
US6495700B1 (en) | 2002-12-17 |
HUP0500747A3 (en) | 2009-05-28 |
KR20060097772A (ko) | 2006-09-15 |
HK1075659A1 (en) | 2005-12-23 |
KR100712003B1 (ko) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5535082B2 (ja) | ボセンタン、その多形形態及びその塩の合成方法 | |
JP2005514459A (ja) | フェンセリン及びその類似体を生成するための方法 | |
JP5622842B2 (ja) | アルキルアミン誘導体の製造方法 | |
JPH04288096A (ja) | 3−オキソ−4−アザ−アンドロスト−1−エン 17β−ケトンの新製造方法 | |
US7345206B2 (en) | Process for the dimerisation of alkyl glyoxals | |
JP4457496B2 (ja) | 4−[(2’,5’−ジアミノ−6’−ハロゲンピリミジン−4’−イル)アミノ]シクロペント−2−エンイルメタノールの製造方法 | |
EP2547663A1 (en) | A process for the preparation of highly pure ambrisentan | |
JP2009035560A (ja) | 二置換チアゾールの製造法 | |
EP0432898B1 (en) | Glutaric acid derivatives and preparation thereof | |
CN113698310B (zh) | 一种恩杂鲁胺双酯中间体的制备方法 | |
JP2001199916A (ja) | ヒドロキシベンジルアルコール類の製造方法 | |
JP3272340B2 (ja) | 1−[(シクロペント−3−エン−1−イル)メチル]−5−エチル−6−(3,5−ジメチルベンゾイル)−2,4−ピリミジンジオンの製造方法 | |
JP2894366B2 (ja) | デアセチルコルヒチンの製造方法 | |
JPH11292869A (ja) | イプリフラボンの製法 | |
JP2005145833A (ja) | Syn−1,3−ジオール化合物の製造方法 | |
KR100516383B1 (ko) | 디히드로카보스트릴 유도체의 신규 제조방법 | |
HK1075659B (en) | A process for producing phenserine and its analog | |
KR950008527B1 (ko) | 피리딘 유도체의 제조방법 | |
CN115181093A (zh) | Sunvozertinib中间体的制备方法 | |
CN109438449A (zh) | 一种含六氢哒嗪酸结构的西拉普利的合成方法 | |
JP2008208063A (ja) | 4,5−ジメチル−[1,3]ジセレノール−2−セロンの新規製造方法 | |
JP2004538284A (ja) | 4−アミノ−4−フェニルピペリジン類の製造方法 | |
JPH08208618A (ja) | 4a−アリ−ルデカヒドロイソキノリン類の製造法 | |
JPH082822B2 (ja) | 置換フェノキシアルキルアルデヒドジアルキルアセタ−ル類およびその製造方法 | |
KR20010034123A (ko) | 3-메틸-2-옥소인돌린의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080520 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080820 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090313 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090323 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090811 |